Argonne maintains a wide-ranging science and technology portfolio that seeks to address complex challenges in interdisciplinary and innovative ways. Below is a list of all articles, highlights, profiles, projects, and organizations related specifically to diseases.
Arexvy has been shown to prevent severe illness brought on by respiratory syncytial virus, which affects millions every year. The U.S. Food and Drug Administration has approved Arexvy for people 60 years old or older.
Argonne National Laboratory has developed computer models to predict how disease can spread. With funding from the U.S. Department of Energy, it will work with Sandia National Laboratories algorithms to make them better.
Argonne’s collaboration with the Discovery Partners Institute helps public health officials track COVID variants and infectious diseases across Illinois. The system was honored among the most innovative new products or services brought to market in 2022.